Raymond James Reiterates Outperform Rating on Neurocrine Bio. (NBIX), Company is Well Positioned to Execute as COVID Dissipates
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated an Outperform rating and $125.00 price target on Neurocrine Bio. (NASDAQ: NBIX) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
